NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 125 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 125 is an oral tablet combining carbidopa, levodopa, and entacapone, a COMT inhibitor used to treat Parkinson's disease. Levodopa is converted to dopamine in the brain to restore motor function, while carbidopa prevents premature conversion in the periphery and entacapone extends levodopa availability by inhibiting its breakdown. This triple combination provides more consistent dopaminergic activity throughout the day.
$0.031BPart D
LOE ApproachingDeclining
As LOE approaches, brand teams face shrinking market share and revenue; expect resource consolidation and shift toward generic management or transition to newer Parkinson's therapies.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STALEVO 125 offers experience in mature market management, payer negotiation, and lifecycle strategy during LOE—critical skills for career advancement in pharma. However, limited growth trajectory and shrinking budget make this a transition role best suited for professionals developing expertise in managed decline, generic strategy, or portfolio optimization.
Brand Manager
Worked on STALEVO 125 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.